Search Result

Results for "

BRD9 Degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (3) Epigenetic Reader Domain (33) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (7) Molecular Glues (6) PROTAC Linkers (1) PROTACs (24)
By Research Areas:	Cancer (39) Inflammation/Immunology (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153367

FHD-609 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
FHD-609 is a PROTAC degrader and inhibitor of *BRD9* (Bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment. (Blue: BRD9 ligand-6 (HY-49393), Black: linker (HY-168309); Pink: (S)-Deoxy-thalidomide-Br (HY-168308) ) .

HY-145925B

CFT8634 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
CFT8634 is an orally bioavailable PROTAC BRD9 targeted degrader based on the E3 ubiquitin ligase CRBN mechanism. CFT8634 can be used for the study of synovial sarcoma and SMARCB1-deficient solid tumors (Pink: BRD9 ligand (HY-169988); Blue: E3 ligase ligand (HY-169989); Black: linker (HY-169991). CFT8634 is a heterobifunctional molecule that binds to BRD9 at one end and recruits CRBN at the other end, which can inhibit the growth of tumor cells that depend on BRD9. CFT8634 can be used for the study of SMARCB1-related cancers (such as synovial sarcoma and malignant rhabdoid tumor) .

HY-103632

*PROTAC BRD9* Degrader-1** 3 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD9 Degrader-1 is a PROTAC connected by ligands for Cereblon and *BRD9* (IC₅₀=13.5 nM), which can be used as a selective probe useful for the study of BAF complex biology .

HY-114322

VZ185 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
VZ185 is a potent, fast, and selective von Hippel-Lindau based dual degrader probe of *BRD9* and BRD7 with DC₅₀s of 4.5 and 1.8 nM, respectively. VZ185 is cytotoxic in EOL-1 and A-402 cells, with EC₅₀s of 3 nM and 40 nM, respectively .

HY-159579

CW-3308	PROTACs Epigenetic Reader Domain	Cancer
CW-3308 is an orally active *BRD9* PROTAC degrader with an DC₅₀ of 92 nM. CW-3308 forms a ternary complex with *BRD9* and cereblon to mediate *BRD9* degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces *BRD9* protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors .

HY-155361

*PROTAC BRD9* Degrader-7**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD9 Degrader-7 is an orally active, selective *BRD9* PROTAC degrader (DC₅₀ = 1.02 nM). PROTAC BRD9 Degrader-7 mediates *BRD9* degradation via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-7 exhibits proliferation inhibitory activity in the MV4-11 cells. PROTAC BRD9 Degrader-7 can be used in the research of acute myeloid leukemia and other related malignancies. (Pink: BI 7271: HY-123616, Blue: 5-Aminothalidomide: HY-W023573, Blue + Black: Thalidomide-5-piperazine: HY-W834174, Black: N,N'-Dimethylpiperazine: HY-W539783) .

HY-117690

dBRD9	PROTACs Epigenetic Reader Domain	Cancer
dBRD9,a PROTAC, can selective degrades *BRD9. dBRD9 improves the bromine domain binding profile and reduces the binding activity of the whole BET* family .

HY-172615

AMPTX-1	Molecular Glues Epigenetic Reader Domain	Cancer
AMPTX-1 is a selective, orally active, covalent reversible *BRD9* molecular glue degrader with a DC₅₀ of 0.05 nM. AMPTX-1 selectively recruits *BRD9* to the E3 ligase DCAF16. AMPTX-1 forms a ternary complex with *BRD9* and a reversible covalent adduct with Cys58 on the surface of DCAF16. AMPTX-1 mediates *BRD9* degradation via the proteasome and Cullin RING E3 ligase pathways. AMPTX-1 can be used in the research of solid tumors and hematological malignancies .

HY-148739

dBRD 9-A	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
dBRD 9-A is a selective *BRD9* PROTAC degrader. dBRD 9-A induces near complete *BRD9* degradation dependent on E3 ubiquitin ligase CRBN and *BRD9* bromodomain engagement, and drives loss of *BRD9* chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma .

HY-145403

*PROTAC BRD9* Degrader-4**	PROTACs	Cancer
PROTAC BRD9 Degrader-4 is a BRD9 bifunctional degrader for researching cancer.

HY-162651

*PROTAC BRD9* Degrader-8**	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BRD9 Degrader-8 is a selective, orally active BRD9 PROTAC degrader with a DC₅₀ of 16 pM.\nPROTAC BRD9 Degrader-8 induces cell cycle arrest at the G1 phase and promotes apoptosis. PROTAC BRD9 Degrader-8 can be used for research on acute myeloid leukemia and diffuse large B-cell lymphoma .

HY-156744

DBr-1	PROTACs Epigenetic Reader Domain	Cancer
DBr-1 is a potent *BRD9* PROTAC degrader (K_D: 13 nM). DBr-1 can overcome intrinsic resistance to VHL-degrader. Blue: DCAF1 binder (HY-149934), Black: linker, Pink: BRD9/BRD7 bromodomains inhibitor (HY-100352) .

HY-W023573

5-Aminothalidomide	Ligands for E3 Ligase	Cancer
5-Aminothalidomide is an E3 ligase ligand used in PROTAC technology. 5-Aminothalidomide can be used to synthesize various PROTACs, such as the PROTAC *BRD9* Degrader-7 (HY-155361).

HY-145400

*PROTAC BRD9* Degrader-3**	PROTACs	Cancer
PROTAC BRD9 Degrader-3 is a BRD9 bifunctional degrader for researching cancer.

HY-163811

BRD9 Degrader-4	Molecular Glues Epigenetic Reader Domain	Cancer
BRD9 Degrader-4 (BRD9c), a bifunctional molecular glue, is a potent *BRD9* degrader with a DC₅₀ of ≤25 nM. BRD9 Degrader-4 has anti-cancer effects .

HY-156401

BRD9 Degrader-1	PROTACs Epigenetic Reader Domain	Cancer
BRD9 c-1 (Compound 13-7) is a PROTAC *BRD9* degrader . BRD9 Degrader-1 has a micromolar binding affinity for BRD9 and a nanomolar affinity for the BRD9-VCB ternary complex. BRD9 Degrader-1 induces BRD9 proteasome degradation in HEK293T cells, which can be reversed by MLN4924 (HY-70062). (Blue: VH032-cyclopropane-F (HY-125905); Black: linker (HY-W763939); Pink: HY-168695) .

HY-177729

*PROTAC BRD9* Degrader-9**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD9 Degrader-9 (Compound 16) is an efficient and selective targeting BRD9 PROTAC degrader. PROTAC BRD9 Degrader-9 does not cause significant cytotoxicity. PROTAC BRD9 Degrader-9 can be used for cancer research

HY-163810

BRD9 Degrader-3	Molecular Glues Epigenetic Reader Domain	Cancer
BRD9 Degrader-3 (compound B20) is a *BRD9* molecular glue, with a DC₅₀ of <1.25 nM .

HY-163809

BRD9 Degrader-2	Molecular Glues Epigenetic Reader Domain E1/E2/E3 Enzyme	Cancer
BRD9 Degrader-2 (Compound B11) is a *BRD9* degrader (DC₅₀ ≤1.25 nM; Dmax≥75%). BRD9 Degrader-2 can be used for research of cancers .

HY-145947

*PROTAC BRD9* Degrader-5**	PROTACs	Cancer
PROTAC BRD9 Degrader-5 is a PROTAC for targeted degradation of *BRD9*.

HY-145395

*PROTAC BRD9* Degrader-2**	PROTACs	Cancer
PROTAC BRD9 Degrader-2 is a BRD9 bifunctional degrader for researching cancer.

HY-153632

*PROTAC BRD9* Degrader-6**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD9 Degrader-6 is a potent degrader of *BRD9* (IC₅₀=0.13 nM), can be used for research of BAF complex-related disorders .

HY-178345

ZZ7-23-022 ZZ7	Molecular Glues Epigenetic Reader Domain	Cancer
ZZ7-23-022 (ZZ7) is a selective *BRD9* molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer .

HY-W129531

N-Boc-4,4'-bipiperidine	PROTAC Linkers	Cancer
N-Boc-4,4'-bipiperidine is a PROTAC linker that can be used to synthesize PROTAC BRD9 Degrader-5 (HY-145947) .

HY-181949

*PROTAC BRD9* Degrader-10**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD9 Degrader-10 is a PROTAC degrader targeting *BRD9, with an IC₅₀* of 2.97 μM against *BRD9. PROTAC BRD9* Degrader-10 induces *BRD9* degradation via the ubiquitin-proteasome system by recruiting the VHL E3 ubiquitin ligase. PROTAC BRD9 Degrader-10 reduces the viability and inhibits the proliferation of myeloid leukemia cells. PROTAC BRD9 Degrader-10 is applicable for the research of acute myeloid leukemia .

HY-181951

*PROTAC BRD9* Degrader-11**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD9 Degrader-11 is a VHL-based *BRD9* PROTAC degraderwith an IC₅₀ of 0.66 μM. PROTAC BRD9 Degrader-11 induces selective, proteasome-dependent degradation of BRD9 via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-11 impairs cell viability, suppresses proliferation, and arrests growth of acute myeloid leukemia cells. PROTAC BRD9 Degrader-11 can be used for the research of acute myeloid leukemia .

HY-178043

BTR2038	Epigenetic Reader Domain	Others
BTR2038 is a *BRD9* degrader. BTR2038 consistis of a BRD9 bromodomain ligand (Bl-7273 analoag), a linker and BTR2000 (HY-172563). BTR2038 induces targeted degradation of V5-tagged human *BRD9. BTR2038 can be used for the study of biological processes and diseases associated with abnormal BRD9* protein function .

HY-117690A

dBRD9 dihydrochloride	PROTACs Epigenetic Reader Domain	Cancer
dBRD9 dihydrochloride is a selective *BRD9* PROTAC degrader. dBRD9 dihydrochloride inhibits proliferation of AML cell lines .

HY-130853

Thalidomide-NH-PEG2-C2-NH-Boc	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized?E3 ligase ligand-linker conjugate?that incorporates the?Thalidomide?based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis. dBRD9 is a selective *BRD9* probe PROTAC degrader for the study of BAF complex biology .

HY-168695

BRD9 ligand-7	Ligands for Target Protein for PROTAC	Cancer
BRD9 ligand-7 is a Ligand for Target Protein for PROTAC. CSI118 TFA can be used to synthesize BRD9 Degrader-1 (HY-156401) .

HY-114322A

cis-VZ185	PROTACs Epigenetic Reader Domain	Others
cis-VZ185 is a VHL-based PROTACs degrader with the activity of degrading BRD9 and BRD7. cis-VZ185 can be optimized from suboptimal compounds by optimizing the connection mode and linker, and has efficient, rapid and selective degradation of BRD9 and its homologous protein BRD7.

HY-150797

QA-68 QA-68-ZU81	PROTACs Epigenetic Reader Domain	Inflammation/Immunology Cancer
QA-68 (QA-68-ZU81) is an effective PROTAC-class *BRD9* degrader. QA-68 can inhibit cell cycle progression and cell colony formation. QA-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines . QA-68 can be formed by a target protein ligand (red part) EA-89 (HY-170314), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-I (HY-131318), and a PROTAC linker (black part) Ethyne-C2-Pip-CO-Pip-Boc (HY-170315). E3 ubiquitin ligase and linker can form Lenalidomide-ethyne-C2-Pip-CO-Pip (HY-170319).

HY-W877239

Pomalidomide 7'OMe	Ligands for E3 Ligase	Cancer
Pomalidomide 7'OMe is a E3 ligase ligand that can be used in the recruitment of CRBN protein. Pomalidomide 7'OMe can be connected to the BRD9 ligand (HY-107446) by a linker to synthesis of PROTAC BRD9 degrader-9 (HY-177729) .

HY-145925C

(S,R)-CFT8634	PROTACs Epigenetic Reader Domain	Cancer
(S,R)-CFT8634 (compound 176) is a selective and orally active PROTAC-class *BRD9* protein degrader. (S,R)-CFT8634 has the potential to study BRD9-mediated diseases, including but not limited to abnormal cell proliferation. (S,R)-CFT8634 consists of a target protein ligand (red part) BRD9 ligand-5 (HY-169988), an E3 ligase ligand (blue part) CRBN ligand-11 (HY-169989), and a PROTAC linker (black part) 1-(3,3-Difluoro-4-piperidinyl)piperazine (HY-169991). E3 ligase ligand and linker can form E3 Ligase Ligand-linker Conjugate 142 (HY-169990) .

HY-168694

E3 Ligase Ligand-linker Conjugate 147	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 147 is a conjugate of E3 ligase ligand and PROTAC Linker, which can be used to synthesize BRD9 Degrader-1 (HY-156401) (Compound 13-7) . E3 Ligase Ligand-linker Conjugate 147 is composed of the E3 ligase ligand BRD9 ligand-7 (HY-168695) and the PROTA linker 2-((1R,5S,6s)-3-Azabicyclo[3.1.0]hexan-6-yl)ethan-1-ol (HY-W763939).

HY-181952

BRD9 ligand-11	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BRD9 ligand-11 is a *BRD9* PROTAC ligand. BRD9 ligand-11 can be conjugated with E3 ligase Ligand (HY-125845) and linker to synthesize PROTAC BRD9 Degrader-11 (HY-181951). PROTAC BRD9 Degrader-11 can be used for cancer research .

HY-181950

BRD9 ligand-10	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Others
BRD9 ligand-10 is a ligand targeting *BRD9. BRD9* ligand-10 can be used as a target protein ligand for the synthesis of PROTAC BRD9 Degrader-10 (HY-181949) .

HY-175915

BRD9 ligand-13	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Others
BRD9 ligand-13 (Compound 5) is a BRD9 ligand that can be used for the synthesis of PROTACs, such as PROTAC BRD9 Degrader-8 (HY-162651).

HY-184211

BRD9 ligand-14	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BRD9 ligand-14 is a *BRD9* ligand that acts as a protein-of-interest ligand for synthesis of BRD9 PROTAC degraders. BRD9 ligand-14 can be used for research in acute myeloid leukemia .

HY-182084

BRD9 ligand-12	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BRD9 ligand-12 is a *BRD9* ligand. BRD9 ligand-12 can be used as a ligand for target protein for PROTAC to develop and design degradative agents for PROTAC BRD9, such as XYD270 (HY-182082). XYD270 inhibits tumor growth in a mouse model of acute myeloid leukemia. XYD270 can be used in research related to synovial sarcoma and acute myeloid leukemia .

HY-W1115268

E3 Ligase Ligand-linker Conjugate 231	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 231 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 231 can be used for the synthesis of the PROTAC BRD9 Degrader-8 (HY-162651) .

HY-182082

XYD270	PROTACs Epigenetic Reader Domain	Cancer
XYD270 is an orally active *BRD9* PROTAC degrader. XYD270 inhibits the proliferation of cancer cells. XYD270 suppresses tumor growth in a mouse model of acute myeloid leukemia. XYD270 can be used in research related to synovial sarcoma and acute myeloid leukemia .

HY-107446

BI-7273 acid	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Others
BI-7273 acid, BI-7273 (HY-100351) derivative, is a BRD9 PROTAC ligand. BI-7273 acid can be conjugated with E3 ligase Ligand Thalidomide (HY-14658) and linker to synthesize BRD9 PROTAC degrader dBRD 9-A (HY-148739) .

HY-182766

AMX-883	Molecular Glues Epigenetic Reader Domain	Cancer
AMX-883 a selective and orally active BRD9 molecular glue degrader that drives differentiation in acute myeloid leukaemia. AMX-883 shows selectivity over all other bromodomain containing proteins and proteome wide. AMX-883 does not employ the commonly used E3 ligases (cereblon, VHL) but instead drives degradation via DCAF16 as a targeted glue. AMX-883 can be used for the study of acute myeloid leukaemia (AML) .

5-Aminothalidomide	Biochemical Assay Reagents
5-Aminothalidomide is an E3 ligase ligand used in PROTAC technology. 5-Aminothalidomide can be used to synthesize various PROTACs, such as the PROTAC *BRD9* Degrader-7 (HY-155361).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: